Loerop James 4/A
4/A · Aclaris Therapeutics, Inc. · Filed Feb 5, 2026
Research Summary
AI-generated summary of this filing
Aclaris (ACRS) CBO James Loerop Exercises RSUs; Shares Withheld
What Happened James Loerop, Chief Business Officer of Aclaris Therapeutics (ACRS), had restricted stock units (RSUs) vest and convert into common shares on February 1, 2026. A total of 33,500 RSUs settled into shares (11,250 + 7,500 + 14,750). To satisfy tax withholding obligations, 10,686 of those shares were withheld at $3.51 per share for a cash value of $37,508, leaving a net issuance to Loerop of 22,814 shares. The filings show the RSU conversions recorded as derivative exercises (code M) and the withholding as a tax payment (code F).
Key Details
- Transaction date: February 1, 2026 (reported in amended Form 4 filed Feb 5, 2026).
- Shares settled: 33,500 RSUs converted to common stock (11,250; 7,500; 14,750).
- Tax withholding: 10,686 shares withheld at $3.51/share = $37,508 (code F).
- Net shares delivered to insider: 22,814 (33,500 − 10,686).
- Post-transaction total shares owned: not specified in this filing.
- Footnotes: F1–F5 describe that these were restricted stock units (each RSU = one share) with multi-year vesting schedules (grants dated Feb 1 of 2022, 2023, and 2024) and F2 confirms shares were withheld to satisfy tax withholding.
- Amendment: This Form 4 amends the Feb 3, 2026 filing that incorrectly reported a Feb 1, 2025 transaction date — the amendment corrects that error.
- Transaction codes: M = exercise/conversion of derivative (RSU settlement); F = payment of tax liability via share withholding. No 10b5-1 plan or 10% owner status was reported.
Context This was a routine settlement of vested RSUs, not an open-market purchase or sale. The withholding of shares to cover taxes is a common, administrative step (similar to a cashless exercise) and does not by itself indicate buying or selling sentiment in the market.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-01+11,250→ 165,758 total - Exercise/Conversion
Common Stock
[F1]2026-02-01+7,500→ 173,258 total - Exercise/Conversion
Common Stock
[F1]2026-02-01+14,750→ 188,008 total - Tax Payment
Common Stock
[F2]2026-02-01$3.51/sh−10,686$37,508→ 177,322 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-02-01−11,250→ 0 total→ Common Stock (11,250 underlying) - Exercise/Conversion
Resticted Stock Units
[F1][F4]2026-02-01−7,500→ 7,500 total→ Common Stock (7,500 underlying) - Exercise/Conversion
Restricted Stock Units
[F1][F5]2026-02-01−14,750→ 29,500 total→ Common Stock (14,750 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
- [F3]The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
- [F4]The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
- [F5]The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.